Royalty Report: Drugs, Delivery, Therapeutic – Collection: 237220


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Delivery
  • Therapeutic
  • Pharmaceuticals

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 237220

License Grant
Licensor grants an exclusive license, under the Licensor Patents, the Licensor Technology, the Joint Developments, the TIMERx Improvements and Licensor s Confidential Information disclosed to Licensee, to manufacture, use and sell and register the Designated Product in the Territory during the License Term.

Licensor grants a nonexclusive license under all rights of Licensor and its Affiliates, in and to the Licensor Test and Regulatory Data to use the same as is necessary for purposes of complying with governmental requirements, but solely with respect to the Designated Product for marketing or use in the Territory.

Licensor grants an exclusive license under any and all rights of Licensor in and to the Licensor Trademark(s), to use the Licensor Trademark(s) solely in connection with the manufacture, distribution, and sale of the Designated Product in the Territory for the term of this Agreement.

License Property
The patents include Directly Compressible Sustained Release Excipient, and, Agglomerated Hydrophilic Complexes with Multi-Phase Release Characteristic, and, Sustained Release Heterodisperse Hydrogel Systems for Insoluble Drugs, and others.

The Designated Product shall mean the solid-dosage form of a controlled-release pharmaceutical for oral administration in humans that combines a racemic mixture of metoprolol tartrate with TIMERx and other excipients, which exhibit is subject to modifications as the Parties may mutually agree during the Development Period.

The Designated Product is a Solid-dosage form of a controlled-release pharmaceutical for oral administration in humans in a 24 hour release form in a 200mg tablet dosage strength that combines a racemic mixture of metoprolol tartrate with TIMERx and other excipients and is eligible for approval, or has been approved, by the FDA under an NDA.

The trademark is TIMERx® Oral Delivery System.

Field of Use
The product is for oral administration in humans.

IPSCIO Record ID: 27061

License Grant
The Company has previously agreed to pay royalties to CONSULTANT, a member of the Company's Board of Directors, in recognition of the patents developed by CONSULTANT for TIMERx.
License Property
The Company has developed the TIMERx delivery system, a novel drug delivery technology, to address the limitations of currently available oral controlled release delivery systems. The Company believes that the TIMERx system is a major advancement in oral drug delivery that represents the first easily-manufactured oral controlled release drug delivery system that is applicable to a wide variety of drug classes, including soluble drugs, insoluble drugs and drugs with a narrow therapeutic index. The Company is utilizing the TIMERx system to formulate generic versions of branded controlled release drugs, controlled release formulations of currently-marketed.

The TIMERx drug delivery system is a hydrophilic matrix combining primarily a heterodispersed mixture, usually polysaccharides xanthan and locust bean gums, in the presence of dextrose. The physical interaction between these components works to form a strong, binding gel in the presence of water. Drug release is controlled by the rate of water penetration from the gastrointestinal tract into the TIMERx gum matrix, which expands to form a gel and subsequently releases the active drug substance. The TIMERx system can precisely control the release of the active drug substance in a tablet by varying the proportion of the gums, together with the third component, the tablet coating and the tablet manufacturing process. Drugs using TIMERx technology are formulated by combining the active drug substance, the TIMERx drug delivery system and additional excipients and compressing such materials into a tablet.

1)  Directly compressible sustained release excipient.

2)  Sustained release excipient and tablet formulation.

3)  Compressible sustained release solid dosage forms.

4)  EPO Application No. 89309518.2; filed September 19, 1989.

5)  Australian Patent Application No. 43057/89

6)  Japanese Patent Application No. 1-510135

7)  Irish Patent Application No. 2968/89

8)  Canadian Patent Application No. 611,700

9)  Verapamil Tablet Application, Serial No. 736,031 & EPO PCT Applications.

10)  2 U.S. Applications on Bi-modal release.

IPSCIO Record ID: 178743

License Grant
Australian Licensor shall grant an exclusive license to the Pellet Technology for the remainder of the term of this Agreement for the sole purpose of manufacturing and selling the Formulated Product in the Territory.
License Property
Licensor is engaged in the development of certain Pellet Technology to enable Licensor to manufacture Pellets.  The pellet is a tablet dosage form containing pseudoephedrine hydrochloride in sustained release pellets compressed into tablets with pseudoephedrine hydrochloride and terfenadine, approved by the U.S. FDA as an A/B rated substitutable equivalent of Marion Merrell Dows Seldane  D tablets.

The present invention relates to a pharmaceutical tablet composition for oral administration comprising extended-release pseudoephedrine together with a second active drug in an immediate release form.

Field of Use
Licensee is engaged in the development of certain Tabletting Technology.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.